On January 4, 2015, the Board of Directors of Nephros, Inc. appointed Paul A. Mieyal, a member of the Board, to serve as the Acting President, Acting Chief Executive Officer, Acting Chief Financial Officer and Acting Secretary of the company. Dr. Mieyal succeeds John C. Houghton, whose separation of employment as President, Chief Executive Officer and Acting Chief Financial Officer of the Company was effective on January 4, 2015. In addition, Mr. Houghton resigned as a member of the Board, effective on January 4, 2015.
The resignation as a member of the Board was not due to any disagreement by or with Mr. Houghton on any matter relating to the Company's operations, policies or practices. Additionally, Daron Evans has been appointed Chairman of the Board. Mr. Evans will continue to serve as Chairman of the Audit Committee.
Dr. Mieyal has served as a director of the Company since September 2007. Dr. Mieyal has been a Vice President of Wexford Capital LP since October 2006.
Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. It operates through the Water Filtration segment. In the medical markets, it sells water filtration products. In the commercial markets, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Its products are marketed primarily to the food service, hospitality, convenience store, and health care markets. These commercial products are also marketed into medical markets, as supplemental filtration to its medical filters. The Companyâs filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.
NEPHROS, INC. 
